Optimize Safety, Drive Clinical Response and Explore In Vivo, Allogeneic & Autologous Approaches to Spearhead the Next Frontier of Cell Therapy Innovation in Autoimmune Disease
The 4th Cell Therapy for Autoimmune Disease Summit returns to Philadelphia as autoimmune disease emerges as one of the most important growth opportunities in cell therapy. With major fundraising successes such as RegCell's $66 million financing to advance its immune tolerance platform and TRexBio's recent $116.7 million IPO, increased pharma participation from teams like Moderna, and pivotal clinical data expected across autologous, allogeneic, and in vivo approaches, the next 12 months will play a critical role in determining which strategies move the field forward.
Bringing together biopharma, academic, and investment leaders across a range of autoimmune indications, this summit explores the scientific, clinical, and commercial developments shaping the future of autoimmune cell therapy.
Following a wave of encouraging proof-of-concept studies, attention is turning toward the challenge of translating early success into durable therapies that can reach broader patient populations. Through perspectives from teams advancing autologous, allogeneic, and in vivo approaches, attendees will gain insight into the strategies, clinical experiences, and development priorities driving progress across the field.
"The rapid and remarkable expansion of research in the use of cell therapy to treat autoimmune diseases has revealed the great potential for these novel approaches to transform the lives of patients with these challenging diseases."
Peter Merkel, Professor of Medicine Rheumatology, University of Pennsylvania
"Cell therapies for autoimmune diseases have entered a new phase in 2026 with promising clinical data and recent approvals across multiple modalities including T regulatory, CAR-T, and in vivo engineered cell therapies."
Dan Shelly, Chief Business Development Officer, Immuthera / PolTREG
"The conference had a great set of attendees from academia, biotech and large pharma. This facilitated progressive and open discussion during talks, panels and roundtables."
Thomas Furmanak, Director - Translational Medicine, Cabaletta Bio
“The conference was great. I made important contacts and met interesting people. Great information exchange opportunity! Will definitely come again next year!”
Senior Scientist, Clinical Immunology, Cartesian Therapeutics, 2025 Delegate
Two Dedicated Tracks
Preclinical & Developmental Strategies
This track is designed for discovery, preclinical, and translational leaders looking to understand which approaches are most likely to succeed as autoimmune cell therapy enters its next phase of growth.
Learn how organizations are leveraging improved preclinical models, identifying novel targets beyond CD19, developing in vivo approaches to reduce cost of goods, and achieving clear immune reset via B-cell targeting. Hear from Sail Biomedicines, Alloplex Biotherapeutics, and Kite Pharma.
Clinical Development Deep Dives Beyond the Data
This track is designed for clinical, translational, and business leaders seeking to understand how cell therapies are progressing from breakthrough proof-of-concept studies toward broader adoption.
Discussions will focus on translating early successes into scalable, commercially viable therapies. Hear directly from pioneers at Cabaletta Bio, Quell Therapeutics, PolTREG, and more as they share lessons from advancing therapies toward pivotal clinical trials, improving patient outcomes, and expanding access to these potentially transformative treatments.
Access Your Copy of the Agenda to Discover:
- 25+ Industry & Academic Leaders sharing the data and lessons learned, shaping the future of autoimmune cell therapy
- 2 Dedicated Tracks to provide every member of your organization a personalized experience and return with actionable insights
- 8+ Hours of Structured Networking to connect with global autoimmune leaders
- An Exclusive Investor & Pharma Insights Panel outlining the qualities they look for when funding the next generation of autoimmune cures
- Clinical, Translational & Commercialization Insights that are essential for the continued progress and scaling of cell therapies
The 2026 World-Class Speaker Faculty Includes:
2026 Partner
Attending Companies Include
Explore Related Events
![CB-CDx-0690-min-scaled11[1]](https://cell-therapy-autoimmune-disease.com/wp-content/uploads/sites/286/2024/06/CB-CDx-0690-min-scaled111.jpg "CB-CDx-0690-min-scaled11[1]")
Explore the Agenda
Discover the latest clinical breakthroughs, translational advances, and commercialization strategies shaping autoimmune cell therapy.
Partner With Us
Connect with the industry's leading autoimmune cell therapy developers as they navigate the next phase of clinical and commercial growth.
Join Cell Therapy Leaders
With major clinical milestones and growing pharma investment, attend a highly focused meeting designed specifically for autoimmune disease to connect with the leaders driving the next phase of progress.